# A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Source: https://onco.cc/trials/nct06271837/  
OnCo record `nct06271837` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab deruxtecan and Bevacizumab in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors is a phase 2 interventional study registered as NCT06271837 by AstraZeneca, with 127 participants enrolled, started 2024-02-22 and due to reach its primary completion in 2027-02-10. Interventions recorded: Trastuzumab deruxtecan and Bevacizumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06271837
- Phase: 2
- Setting: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as Monotherapy or in Combination With Anti-cancer Agents for the Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03)
- Sponsor: AstraZeneca
- Enrolled: 127

## Sources

- ClinicalTrials.gov NCT06271837: https://clinicaltrials.gov/study/NCT06271837

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct06271837.json